First disease-modifying therapy for NHS use to delay the onset of type 1 diabetes recommended
A first-of-its-kind therapy that can delay the onset of type 1 diabetes for up to 3 years is to be made available on the NHS.
A first-of-its-kind therapy that can delay the onset of type 1 diabetes for up to 3 years is to be made available on the NHS.
The treatment uses a targeted therapy that seeks out a specific protein found on the surface of cancer cells and delivers a cancer-killing medicine directly to them.
Women with type 1 diabetes who are pregnant or planning a pregnancy should be offered a pregnancy-specific 'artificial pancreas' device. That is the recommendation in draft guidance published today by NICE.
A consultation has begun on draft guidance recommending 4 specialist liver preservation machines for routine NHS use, which could help more of the 600 people in England waiting for a life-saving transplant.
This World Sickle Cell Day we’re sharing Jimi Olaghere’s story. Jimi was one of the first people in the world to receive CRISPR gene therapy. Jimi’s story show’s why our recommendation for this treatment on the NHS is so important.
Debra Quantrill was out with her 2 young children when she had a life-changing heart attack. Now she’s using her experience to help others as a patient representative on one of our independent committees.
Learn how our evidence-based guidance helped a London NHS trust standardise procurement and generate operational efficiencies.
Learn how NICE's healthtech guidance is accelerating NHS adoption of a simple bowel cancer test, preventing 140,000 unnecessary urgent referrals a year while keeping cancer detection rates stable.
